In this issue:
Withdrawing infliximab or immunosuppressants in CD after combination therapy
Sleep duration and daytime napping: relationship with incident IBD
Predictors of vedolizumab clearance in childhood/young adulthood IBD
Characteristics and effect of anxiety and depression trajectories in IBD
Early management of acute severe UC in the biologics era
Blood protein profiles associated with clinical relapse risk in CD after stopping infliximab
Post partum infection risk after caesarean or vaginal delivery in women with IBD
Maintenance tofacitinib for UC according to baseline MES
Please login below to download this issue (PDF)